Diabetic Neuropathy Pathological Research Services
In-depth investigation of the pathological mechanisms of diabetic neuropathy is the key to developing effective therapeutics. As a professional preclinical contract research organization in diabetes, Ace Therapeutics provides professional diabetic neuropathy pathology research services to research institutes and pharmaceutical companies, helping to overcome diabetic neuropathy research and drug development.
Introduction to The Pathogenesis of Diabetic Neuropathy
The pathogenesis of diabetic neuropathy is complex, involving multiple levels of metabolic disorders, vascular injury, and neurotrophic factor deficiency.
- Under chronic hyperglycemia, hyperactivation of the polyol pathway leads to intracellular accumulation of metabolites like sorbitol, triggering cellular osmotic imbalance and oxidative stress.
- Activation of the protein kinase C (PKC) pathway can damage neurovascular endothelial cells, resulting in neural ischemia and hypoxia.
- The massive production of advanced glycosylation end products (AGEs) binds to cell surface receptors, further exacerbating the inflammatory response and nerve damage.
- Impaired synthesis and transport of trophic factors, such as nerve growth factor (NGF), also affects the normal function and repair of nerve cells and accelerates the development of neuropathy.
These mechanisms interact with each other to drive the onset and progression of diabetic neuropathy.
Fig. 1 Pathophysiology of diabetic peripheral neuropathy. (Baum, P. et al., 2021)
Our Diabetic Neuropathy Pathological Research Services
Ace Therapeutics is dedicated to helping clients gain deep insights into the unique mechanisms of neural damage under hyperglycemic conditions by leveraging our in vivo and in vitro models as well as advanced technologies, thereby providing a scientific foundation for novel target discovery and translational research.
Diversified Diabetic Neuropathy Modeling
We provide a variety of well-established animal models of diabetic neuropathy, such as streptozotocin (STZ)-induced rat and mouse models, and spontaneous diabetes animal models. These models can simulate the pathological features of human diabetic neuropathy, including nerve fiber degeneration, demyelination changes, and slowed nerve conduction velocity, etc., providing reliable experimental subjects for research. Meanwhile, special models can be customized according to clients' demands.
| Animal Models |
- Conventional Chemically Induced Models: Streptozotocin (STZ)- or alloxan-induced diabetic rat/mouse models.
- Genetically Engineered Models: Knockout of diabetes susceptibility genes (e.g., Akr1b10 knockout) or transgenic mouse models.
- Specialized Neuropathy Models: Peripheral neuropathy models (e.g., sciatic nerve injury model) and autonomic neuropathy models (e.g., cardiac autonomic dysfunction model).
|
| Cell Models |
- High-glucose culture models of dorsal root ganglion (DRG) neurons and Schwann cells.
- Neuron-endothelial cell co-culture models (e.g., co-culture of neurons with vascular endothelial cells).
|
Pathological Mechanism Research Services
We help clients investigate the pathological mechanisms of diabetic neuropathy from multiple perspectives, such as metabolic disorders, vascular damage, oxidative stress, and inflammatory response, to support the discovery of novel therapeutic targets.
| Mechanisms of Metabolic Dysregulation |
Focuses on the neuronal damage caused by metabolic dysregulation induced by hyperglycemia, including polyol pathway activation, protein kinase C (PKC) activation, and hexosamine pathway upregulation. |
| Studies on Vascular and Neurotrophic Impairment |
Investigating the impact of microvascular changes (such as basement membrane thickening and vascular endothelial dysfunction) and neurotrophic factor deficiencies (e.g., NGF, BDNF) on nerve fibers. |
| Oxidative Stress and Inflammatory Response Studies |
Analyzing neuronal apoptosis and myelin damage resulting from reactive oxygen species (ROS) accumulation and NF-κB pathway activation. |
| Genetic and Epigenetic Studies |
Investigating the roles of diabetes‑associated genes (e.g., aldose reductase gene) and epigenetic modifications (e.g., DNA methylation, histone acetylation) in diabetic neuropathy (DN). |
Our Advanced Technology Platform
- Our experimental platform is equipped with state-of-the-art instruments including high-resolution microscopy, confocal laser scanning microscopy, flow cytometry, and mass spectrometry, enabling precise analysis and investigation of the pathological processes in diabetic neuropathy.
- By integrating bioinformatics analysis, we conduct in‑depth mining of large-scale experimental data to reveal underlying pathological mechanisms and therapeutic targets.
- We have established a comprehensive in vivo dynamic functional assessment system for neuropathy, such as nerve conduction velocity measurement and behavioral analysis of thermal/nociceptive sensory abnormalities, enabling longitudinal and quantitative monitoring of diabetic neuropathy onset and progression to provide critical functional data for therapeutic efficacy evaluation.
Leveraging professional services and cutting-edge technologies, Ace Therapeutics assists clients in delving into the pathological mechanisms of diabetic neuropathy. We are committed to facilitating the development of more effective therapeutic approaches. For further details, please contact us.
References
- Zhu, J. et al. Diabetic peripheral neuropathy: pathogenetic mechanisms and treatment. Frontiers in endocrinology. 14 (2024): 1265372.
- Baum, P. et al. Inflammatory mechanisms in the pathophysiology of diabetic peripheral neuropathy (DN)—new aspects. International Journal of Molecular Sciences. 22.19 (2021): 10835.
All of our services and
products are intended for preclinical research use only and cannot be used to diagnose, treat or
manage patients.
Related Services
Related Products
